EUVIMEDEUVIMED entdecken
Multizentrische Studie

Menopausal hormone therapy and risk of esophageal and gastric cancer in a multinational study

Victoria Wocalewski iD, Giola Santoni, Helgi Birgisson, My Von Euler-Chelpin iD, Joonas H Kauppila iD, Eivind Ness-Jensen iD, Shaohua Xie iD, Jesper Lagergren iD

JNCI: Journal of the National Cancer Institute · 01.08.2026 · 118 (8) · 1436-1443

DOI: 10.1093/jnci/djag072 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 15.03.2026. Verfasst von Victoria Wocalewski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sw…. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Adenocarcinoma, Menopause. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Swedish Cancer Society, Stockholm County Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The incidence of esophago-gastric cancer has an age-dependent male predominance mirroring the physiological sex differences in sex hormonal levels. Some research suggests that menopausal hormone therapy counteracts these tumors to occur, but larger studies with longer follow-up are needed, which prompted this study.

Methods

This population-based case-control study included women aged 45 years and older in the 5 Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden) between 1995 and 2020. Prospectively collected data came from national registries for medications, cancer, diagnoses, total populations, and death. Menopausal hormone therapy use was categorized as nonuse (referent) and 3 equal-sized groups (tertiles) of defined daily doses (DDDs). Esophago-gastric cancer was divided into esophageal or cardia adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma. Multivariable logistic regression provided odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for multiple confounders.

Results

The study included 19 518 esophago-gastric cancer patients and 195 094 control participants matched for age, calendar year, and country. Compared with nonuse, the adjusted odds ratios of esophageal or cardia adenocarcinoma were 0.74 (95% CI = 0.67 to 0.81) for low menopausal hormone therapy use (<158 DDDs), 0.68 (95% CI = 0.61 to 0.75) for intermediate menopausal hormone therapy use (158-848 DDDs), and 0.68 (95% CI = 0.66 to 0.81) for high menopausal hormone therapy use (>848 DDDs). The corresponding odds ratios were 0.69 (95% CI = 0.62 to 0.77), 0.70 (95% CI = 0.62 to 0.77), and 0.71 (95% CI = 0.64 to 0.79) for esophageal squamous cell carcinoma and 0.90 (95% CI = 0.84 to 0.96), 0.85 (95% CI = 0.79 to 0.91), and 0.80 (95% CI = 0.74 to 0.86) for gastric adenocarcinoma, respectively.

Conclusion

Menopausal hormone therapy users seem to have lower odds of developing esophago-gastric cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsStomach NeoplasmsAdenocarcinomaMenopauseEstrogen Replacement TherapyHormone Replacement TherapyHumansFemaleMiddle AgedCase-Control StudiesAgedRisk FactorsIncidenceOdds RatioRegistriesScandinavian and Nordic Countries

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Upper Gastrointestinal Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Icelandic Cancer Registry, Reykjavik, Iceland.
  • Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
  • Department of Surgery, Oulu University Hospital and University of Oulu, Oulu, Finland.
  • Department of Public Health and Nursing, HUNT Research Center, Norwegian University of Science and Technology (NTNU), Trondheim/Levanger, Norway.
  • Medical Department, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway.

ORCID-Profile: Victoria Wocalewski, My Von Euler-Chelpin, Joonas H Kauppila, Eivind Ness-Jensen, Shaohua Xie, Jesper Lagergren

Förderung

  • Swedish Cancer Society
  • Stockholm County Council

Zitieren

APA

Wocalewski, V., Santoni, G., Birgisson, H., Von Euler-Chelpin, M., Kauppila, J. H., Ness-Jensen, E., Xie, S., & Lagergren, J. (2026). Menopausal hormone therapy and risk of esophageal and gastric cancer in a multinational study. JNCI: Journal of the National Cancer Institute, 118(8), 1436-1443. https://doi.org/10.1093/jnci/djag072

Vancouver

Wocalewski V, Santoni G, Birgisson H, Von Euler-Chelpin M, Kauppila JH, Ness-Jensen E, et al. Menopausal hormone therapy and risk of esophageal and gastric cancer in a multinational study. JNCI: Journal of the National Cancer Institute. 2026;118(8):1436-1443. doi:10.1093/jnci/djag072

BibTeX
@article{Wocalewski2026,
  author = {Wocalewski, Victoria and Santoni, Giola and Birgisson, Helgi and Von Euler-Chelpin, My and Kauppila, Joonas H and Ness-Jensen, Eivind and Xie, Shaohua and Lagergren, Jesper},
  title = {Menopausal hormone therapy and risk of esophageal and gastric cancer in a multinational study},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  volume = {118},
  number = {8},
  pages = {1436--1443},
  doi = {10.1093/jnci/djag072}
}
Kostenlos starten →